Ukraine and Israeli Biotech Firm Sign Agreement to Strengthen Readiness for Nuclear and Radiological Emergencies

Ukraine has signed a landmark agreement with Israeli biotech firm Pluri to create a national emergency response system in case of nuclear or radiological incidents, Times of Israel reported on April, 21.

The partnership includes an exclusive deal with a Ukrainian cord blood bank to stockpile PLX-R18, a cutting-edge therapy developed to treat acute radiation syndrome.

PLX-R18 is a cell-based treatment designed to stimulate the body’s ability to regenerate. It promotes the production of white and red blood cells, as well as platelets, vital components often destroyed by radiation. The therapy also supports bone marrow recovery, potentially helping thousands of patients regain immunity and survive otherwise fatal exposure.

According to agreement, 12,000 doses of PLX-R18 will be manufactured, providing emergency coverage for up to 6,000 individuals. The doses will be cryogenically preserved at Hemafund facilities and made available to Ukrainian hospitals in case of emergency.

Earlier, a Russian drone strike impacted a nuclear shelter located above Reactor 4 at the Chornobyl Nuclear Power Plant. Preliminary assessments indicated that the drone strike caused significant damage to the shelter and there is a risk of possible radiation leaks. However, radiation levels remain stable and are under continuous monitoring.

DEFENSE

Support the Armed Forces of Ukraine

Donate Towards Robots, as Well as Other Military Equipment and Supplies to Help Ukraine’s Defenders Fight Off Russian Invaders

Donate